1. Hornykiewicz O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol Rev 1966;18:925–64.
2. Jankovic J. Parkinson’s disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368–76.
3. Kung HF, Pan S, Kung MP, Billings J, Kasliwal R, Reilley J, et al. In vitro and in vivo evaluation of [123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. J Nucl Med 1989;30:88–92.
4. Kung HF, Alavi A, Chang W, Kung MP, Keyes JW, Velchik MG, et al. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans. J Nucl Med 1990;31:573–9.
5. Brücke T, Podreka I, Angelberger P, Wenger S, Topitz A, Küfferle B, et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab 1991;11:220–8.